UBS Maintains Buy on Steris, Lowers Price Target to $270
UBS analyst Patrick Wood maintains Steris (NYSE:STE) with a Buy and lowers the price target from $275 to $270.
Read original at benzingaStocks · News reference
Steris Widens FY2027 Adj EPS Guidance from $11.10-$11.30 to $11.00-$11.30 vs $11.16 Est; Affirms FY2027 Sales Guidance of $6.352B-$6.411B vs $6.371B Est
Steris (NYSE:STE) widens FY2027 Adj EPS guidance from $11.10-$11.30 to $11.00-$11.30 vs $11.16 analyst estimate. Affirms FY2027 sales outlook from $6.352 billion-$6.411 billion to $6.352 billion-$6.411 billion vs $6.371
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 5, 2026, 8:32 PM
- Checked
- Aug 5, 2026, 8:32 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Piper Sandler Reiterates Overweight on Steris, Raises Price Target to $275
Piper Sandler analyst Jason Bednar reiterates Steris (NYSE:STE) with a Overweight and raises the price target from $270 to $275.
Read original at benzingaSteris Q1 Sales $1.493B Miss $1.498B Estimate
Read original at benzinga8-K filing — STERIS plc (STE)
Filed: 2026-08-05 AccNo: 0001628280-26-053412 Size: 612 KB Item 2.02: Results of Operations and Financial Condition Item 2.05: Cost Associated with Exit or Disposal Activities Item 9.01: Financial Statements and Exhibits
Read original at edgar